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Previewsautophagosomes. These findings support
amodel where dysfunctionalmitochondria
that accumulate in effector NK cells are
cleared by mitophagy, allowing for differ-
entiation of MCMV-specific memory NK
cells (Figure 1). The authors demonstrated
a requirement for autophagic activity dur-
ing the formation of MCMV-specific mem-
ory NK cells using mice with a tamoxifen-
inducible deletion of Atg3, which encodes
an essential autophagosome component.
Deletion of Atg3 during the proliferative
phase following MCMV infection did not
impact the expansion of Ly49H+ NK cells;
however it resulted in a marked reduction
of the ensuing pool of memory NK cells.
While compelling, the experimental evi-
dence provided leaves open the possibility
that Atg3 deletion per se might result
in reduced NK cell homeostasis, regard-
less of this specific memory context.
Providing further support for their hypo-
thesis, O’Sullivan et al., showed that
by enhancing autophagy, through the
inhibition of mTOR or activation of AMP
activated protein kinase, an expanded
number of memory NK cells was gener-
ated. Autophagy was connected to the
clearance of dysfunctional mitochondria,
since increased mitochondrial numbers,
poor mitochondrial quality, and higher
amounts of mitochondrial-associated re-
active oxidative species (ROS) were seen
during the transition from effector to mem-220 Immunity 43, August 18, 2015 ª2015 Elsory type cells in NK cells lacking Atg3
(O’Sullivan et al., 2015). Mitochondrial
dysfunction was linked to the survival
defect of Atg3-deficient memory NK
cells since this phenotype was rescued
by N-acetylcysteine, a ROS scavenger.
BNIP3 and BNIP3L (Nix) are mitochondrial
receptors that promote mitophagy by re-
cruiting the autophagosome via binding
to LC3 proteins. O’Sullivan et al. also
demonstrated that deletion of either
BNIP3 or BNIP3L resulted in accumulation
of dysfunctional mitochondria, impaired
mitophagy, and a markedly decreased
MCMV-specific memory NK cell pool.
Importantly, deletion of BNIP3 or BNIP3L
did not affect normal NK cell development
or function followinghomeostatic prolifera-
tion, highlighting the importanceofmitoph-
agy specifically duringmemoryNKcell for-
mation. These findings also lead to new
mechanistic questions of how BNIP3 and
BNIP3L are regulated in NK cells to selec-
tively induce mitophagy during a memory
response. Is there a direct connection be-
tween mitophagy and antigen-specific
NK cell responses? Further, do other
types of T and NK cell memory, or other
aspects of NK cell biology, depend upon
(or are they limited by) autophagy or
mitophagy?
In summary, this study identifies a novel
requirement for mitophagy in the forma-
tion of virus-induced NK cell memory andevier Inc.pinpoints BNIP3 and BNIP3L as key
mechanistic players not previously impli-
cated in lymphocyte memory formation.
Thus, the hypothesis put forward by
the authors that the need to ‘‘take out the
garbage’’ of damagedmitochondria might
be a general hallmark of immunologic
memory is intriguing and warrants further
study in all adaptive lymphocytes.REFERENCES
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The transcription factor Bcl11b is important for T cell development and maintaining their phenotype. In this
issue of Immunity, Califano et al. (2015) show that Bcl11b has a role in specifying type II innate lymphoid cell
(ILC2) identity and blocks their conversion to ILC3s.It is a remarkable testament to the speed
of progress in modern biological research
that it has been only 6 or 7 years since the
first inklings emerged of the existence of ahitherto unknown subset of lymphocytes
(Satoh-Takayama et al., 2008; Cella
et al., 2009; Luci et al., 2009). Now these
cells are defined as innate lymphoid cells(ILCs) with an ever-expanding set of
critical functions within the immune sys-
tem (Eberl et al., 2015). ILCs have come
to be seen as ersatz T cells for innate
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Previewsimmunity, but with neither antigen-spe-
cific receptors nor the ability to clonally
expand.
ILCs are separated into three subsets—
ILC1s, ILC2s, and ILC3s—based on their
cytokine expression profile, and these
mirror CD4+ T helper cell subsets: T help-
er 1 (Th1), Th2, and Th17 cells. ILC2s are
found on mucosal surfaces and are
important for preventing pathogen inva-
sion and for maintaining tissue homeosta-
sis, mainly by the production of Th-cell-
like cytokines including interleukin-5
(IL-5) and IL-13. ILC2s typically respond
to the cytokines IL-25, IL-33, and thymic
stromal lymphopoietin, which are pro-
duced following parasitic worm infection,
allergen-induced inflammation, or dam-
age to airway epithelial tissue. ILCs, as
well as NK cells, B cells, and T cells, all
develop from the same common
lymphoid progenitors (CLPs). The devel-
opment of ILCs then proceeds further
from distinct progenitor cells, CHILPs
(common helper ILC precursors), which
give rise to all types of ILCs except NK
cells. Much recent work has begun to
reveal the transcriptional network that
controls ILC production in the bone
marrow and their development of effector
functions. The transcription factors Nfil3,
Id2, and Gata3 are critical upstream regu-
lators for the development of all ILC line-
ages. However, the transcription factors
Gata3, RORa, TCF1, and Gfi1 have all
been shown to have a more specific role
in ILC2s.
Bcl11b is a zinc finger transcription
factor that can function as both a tran-
scriptional activator and repressor and
is highly expressed in response to Notch
signaling (Li et al., 2010). Intriguingly,
deletion of Bcl11b in mature T cells al-
lows the expression of many genes
associated with the transcriptional pro-
file of NK cells, hence Bcl11b has a crit-
ical role in maintaining T cell lineage
commitment. The observation that fac-
tors that are known to regulate T cell
development, such as Notch signaling,
are found to enhance ILC2 development
and that Bcl11b has been reported as
highly expressed in ILC2s (Yang et al.,
2013) encouraged researchers to study
Bcl11b in ILC2s.
In this issue of Immunity, Califano et al.
provide definitive evidence for the role of
Bcl11b in specifying ILC2 functional iden-
tity. They first established that Bcl11bprotein was highly expressed in mature
ILC2s taken from lung and mesenteric
lymph nodes (MLNs). Mice with both al-
leles of Bcl11b deleted die around birth
so the study relies on the use of inducible
conditional genetically ablated mice that
delete both Bcl11b alleles in response to
the administration of tamoxifen that mobi-
lizes constitutively expressed Cre recom-
binase fused to an estrogen receptor
(Bcl11bF/Fcre-ERT2). Califano et al. found
that the deletion of Bcl11b had no effect
on total numbers of ILC2s in lungs,
mesenteric lymph nodes (MLNs), and
small intestine lamina propria (siLP), but
did reduce IL-33 receptor expression.
In addition, Bcl11bF/Fcre-ERT2 ILC2s,
showed a significant decrease in the
expression of the ILC2-defining transcrip-
tion factors, Gata3 and Rora, but a
concomitant increase in the ILC3-defining
transcription factor Rorgt. The same cells
produced the ILC3-associated cytokines
IL-22 and IL-17 in response to IL-23, but
no longer produced the ILC2-associated
cytokine IL-13 in response to either IL-33
or IL-25. Similarly, in response to airway
inflammation induced by papain and
following Citrobacter rodentium infection,
the Bcl11bF/Fcre-ERT2 ILC2s produced
ILC3-associated cytokines. The implica-
tion is clearly that deletion of Bcl11b
reversed the phenotype of ILC2s and
induced them to exhibit an ILC3-like
phenotype. These findings were further
supported by RNA-seq analysis of
Bcl11bF/Fcre-ERT2 ILC2s, which showed
the reduced expression of genes broadly
associated with ILC2s such as Gata3
and Gfi1. Rora was unchanged even
though its protein expression was
decreased, suggesting its expression is
regulated in another manner. The same
analysis found that ILC3-associated
genes, such as Ahr, Rorc, Il23r, and
Csf2, were upregulated in the absence
of Bcl11b.
Chromatin immunoprecipitation indi-
cated that Bcl11b can directly bind to po-
tential regulatory regions of the Gfi1 and
Ahr genes in ILC2s. This suggests a
model where Bcl11b directly controls
ILC2 lineage maintenance via Gfi1 while
repressing Ahr expression and a switch
to the ILC3 lineage. Retroviral trans-
duction of Bcl11bF/Fcre-ERT2 ILC2s to
enforce the expression of Gfi1 resulted
in upregulation of Gata3 but reduction in
Rorgt expression. Together the data pre-Immunity 43sented by Califano et al. show that
Bcl11b acts to sustain a mature ILC2
identity, via regulation of Gfi1 and indi-
rectly Gata3 and additionally act to
repress the ILC3 phenotype (Figure 1).
Anyone who has ever tried to catch a
red London bus will be familiar with the
phenomenon where you wait for ages
for one to come along and then three
appear at the same time. And so it is
with papers on the role of Bcl11b in
ILC2s. Two other papers (Walker et al.,
2015 and Yu et al., 2015) have recently
appeared in the Journal of Experimental
Medicine, both dealing with Bcl11b’s
role in ILC2s. All three studies propose
a crucial role for Bcl11b in ILC2s, but
there are significant differences in their
findings.
Both Walker et al. and Yu et al. sug-
gested that Bcl11b expression defines
ILC2 precursors and observed a com-
plete lack of ILC2s in recipient mice re-
constituted with either Bcl11b/ fetal
liver cells or Bcl11b/ bone marrow
hematopoietic progenitors, respectively.
Both groups also detected expression
of Bcl11b in ILC2 progenitors in the
bone marrow and suggested that these
Bcl11b-expressing progenitors were
committed to the ILC2 lineage. In
contrast, Califano et al. detected no
change in the numbers of ILC2 precursors
or mature ILC2s in Bcl11bF/Fcre-ERT2
mice and only detected Bcl11b expres-
sion in mature peripheral ILC2 popula-
tions. The analysis by Walker et al. and
Yu et al. utilized a genetically targeted
mouse where expression of a reporter
gene is a surrogate for endogenous
Bcl11b gene expression, whereas Cali-
fano et al. detected Bcl11b by intracellular
flow cytometry. Detecting endogenous
Bcl11b is likely to be less sensitive than
measuring reporter gene expression,
and this might explain some of the differ-
ences reported.
One other difference between these
reports is that while Califano et al.
showed that potential target genes such
as Gfi1 and Gata3 were downregulated
in ILC2s from Bcl11bF/Fcre-ERT2 mice,
Yu et al. found that ILC2-associated
genes such as Gata3, Rora, and Il13
were upregulated in ILC2s derived from
Bcl11bF/Fcre-ERT2 mice. However, the
latter experiments analyzed expression
following the differentiation of ILC2s puri-
fied from bone marrow and cultured on, August 18, 2015 ª2015 Elsevier Inc. 221
Figure 1. Bcl11b Expression Maintains the ILC2 Phenotype
Loss of Bcl11b allows ILC2s to switch to an ILC3 phenotype. Bcl11b activates the expression of genes
such as Gfi1 and Gata3 that promote the ILC2 phenotype. Loss of Bcl11b led to the repression of Gfi1
and Gata3 and activation of Ahr and Rorc that promote the ILC3 phenotype.
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ligand Delta-like 1 rather than on ILC2s
directly sorted from lungs as in Califano
et al., and this might explain the
discrepancy.
Despite these differences, the three
studies did observe similar responses to
infection in mice with a conditional dele-
tion in Bcl11b mice. Walker et al. and
Califano et al. both observed a failure
to provide ILC2 responses to parasitic
helminth infection but a good ILC3 res-
ponse to Citrobacter rodentium infection.
All three studies therefore agree that
Bcl11b has a key role inmature ILC2 func-
tion, which in part constrains ILC3 activity.
While Bcl11b’s role in mature ILC2s
seems to be clear, further work is required
to conclusively determine its require-
ment in ILC2 precursor development
and its precise role in the hierarchy of
transcription factors that control this
process.
Bcl11b has a well-characterized role
in maintaining T cell identity, and this222 Immunity 43, August 18, 2015 ª2015 Elsseems to be reflected in its function in
ILC2s. The action of promoting the ILC2
phenotype and function while suppress-
ing the ILC3 phenotype seems to be
highly analogous to the role of Bcl11b
in T cells. This effect is made possible
by the dual function of Bcl11b as both
a transcriptional activator and repressor.
This dualism is so common to transcrip-
tion factors involved in lymphocyte
development that it suggests that lym-
phocytes harbor an inherent program to
switch between cell types, the outcome
of which is entirely dependent on circum-
stances. Perhaps this plasticity is an
important characteristic of ILCs and their
function. The switch between ILC3s and
ILC1s in the context of a bacterial infec-
tion has been described (Klose et al.,
2013), so a similar scenario might await
discovery for the ILC2-ILC3 switch.
Indeed, switching between lineages
might be a common motif for ILCs, for
example, in response to infection by
different classes of pathogen. Perhapsevier Inc.it is at the point when ILCs must decide
whether
‘‘to suffer
The slings and arrows of outra-
geous fortune
Or to take arms against a sea of
troubles
And by opposing end them.’’REFERENCES
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